Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support

In 2020, Scandinavian Biopharma entered into an agreement with USAMMDA to fund manufacturing and development activities for its ETEC diarrhoea vaccine, ETVAX®. The agreement has now been extended, providing additional financial support. The objective is to accelerate the development and approval of the vaccine in the United States.
Läs mer